{"id":1560,"date":"2022-04-30T07:21:52","date_gmt":"2022-04-30T07:21:52","guid":{"rendered":"https:\/\/www.invest19.com\/blog\/?p=1560"},"modified":"2022-04-30T07:21:54","modified_gmt":"2022-04-30T07:21:54","slug":"mankind-pharma-to-raise-1-billion","status":"publish","type":"post","link":"https:\/\/www.invest19.com\/blog\/mankind-pharma-to-raise-1-billion\/","title":{"rendered":"MANKIND PHARMA TO RAISE $1 BILLION"},"content":{"rendered":"<div style=\"margin-top: 0px; margin-bottom: 0px;\" class=\"sharethis-inline-share-buttons\" ><\/div>\n<p>The largest Drugmaker in\nIndia, founded by Ramesh Juneja and Rajeev Juneja\nin 1995 is <strong>planning to launch its IPO by the end of the current\ncalendar year. <\/strong>Mankind Pharma, a manufacturer of products like pregnancy\nkits is in the process to launch a $1billion or Rs7600 crore IPO. This will be\none of the largest-ever IPO in the pharma Industry.<\/p>\n\n\n\n<p><strong>Lead bankers for the IPO<\/strong><\/p>\n\n\n\n<p>JM Morgan, Citi, Jefferies, Axis, IIFL, and Kotak has\nbeen hired as investment bankers to manage the $1 billion IPO.<\/p>\n\n\n\n<p><strong>Mankind Pharma\u2019s Product and Market<\/strong><\/p>\n\n\n\n<p>The firm focuses on\ncardiovascular antibiotics, gastrointestinal, antiallergic, anti-fungal,\northopedic, and gynecological segments. The pharma company operates in over 34\noverseas markets with over 14000 employees. Further to expand its footprints in\nthe domestic market, the firm bought formulation brands of Panacea Biotec for\nIndia and Nepal for Rs1,872 crores. Thus helping the company to enter new therapeutic\nareas like oncology transplants.<\/p>\n\n\n\n<p><strong>Offer for sale details of\nthe IPO<\/strong><\/p>\n\n\n\n<p>It will be an offer for sale\nIPO, where existing investor ChrysCapital backed consortium of GIC of Singapore\nand CPP investment own 10%, would shed 1% stake, Capital International owns 11%\nstake will sell 6% stake and the Promoters would sell 3%.<\/p>\n\n\n\n<p><strong>Financial of Mankind Pharma<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>The firm has given a return on equity in FY22\nat a rate of 22.90%.<\/li><li>EBITDA of the company has surged by 29.65%<\/li><li>In 2021-22, the firm posted a revenue of\nRs8000 crores.<\/li><\/ul>\n\n\n\n<p>More details of the Mankind\nPharma will be out as soon as the DRHP is filled with the market regulators\nSEBI. Stay tuned to <a href=\"https:\/\/www.invest19.com\/ipo\/\">Invest19.com<\/a>, to\nknow about the development of Mankind Pharma.<\/p>\n<div class='epvc-post-count'><span class='epvc-eye'><\/span>  <span class=\"epvc-count\"> 3,612<\/span><\/div><div class=\"pld-like-dislike-wrap pld-template-1\">\n    <div class=\"pld-like-wrap  pld-common-wrap\">\n    <a href=\"javascript:void(0);\" class=\"pld-like-trigger pld-like-dislike-trigger \" title=\"\" data-post-id=\"1560\" data-trigger-type=\"like\" data-restriction=\"ip\" data-ip-check=\"0\" data-user-check=\"1\">\n                        <i class=\"fas fa-thumbs-up\"><\/i>\n                    <\/a>\n    <span class=\"pld-like-count-wrap pld-count-wrap\">9    <\/span>\n<\/div><\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>The largest Drugmaker in India, founded by Ramesh Juneja and Rajeev Juneja in 1995 is planning to launch its IPO by the end of the [&hellip;] <span class=\"read-more-link\"><a class=\"read-more\" href=\"https:\/\/www.invest19.com\/blog\/mankind-pharma-to-raise-1-billion\/\">Read More<\/a><\/span><\/p>\n","protected":false},"author":1,"featured_media":1561,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[180,70,10],"tags":[],"class_list":["post-1560","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-ipo","category-featured"],"_links":{"self":[{"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/posts\/1560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/comments?post=1560"}],"version-history":[{"count":1,"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/posts\/1560\/revisions"}],"predecessor-version":[{"id":1562,"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/posts\/1560\/revisions\/1562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/media\/1561"}],"wp:attachment":[{"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/media?parent=1560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/categories?post=1560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.invest19.com\/blog\/wp-json\/wp\/v2\/tags?post=1560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}